Reboost Data Reconfirms 2010 Study

Bionor Pharma’s Phase II Therapeutic HIV Vaccine Vacc-4x: Reboost Data Reconfirms 2010 Study (Oslo, Norway, 28 March 2014)  Bionor Pharma ASA (OSE: BIONOR) announces the results from the Vacc-4x Phase II Reboost trial. The trial explored the effects of Vacc-4x revaccination or reboosting of HIV infected patients that participated in the large 2010 Phase II …

Read more

Bionor Pharma Announces Approval of REDUC Trial

Bionor Pharma ASA announces that the Company has received approval from the Danish Regulatory Agency for its REDUC trial. The REDUC trial is a combination of Bionor Pharma’s lead vaccine candidate Vacc-4x and the Histone DeAcetlyase inhibitor (HDACi) Istodax®(romidepsin). Bionor Pharma further announces that the Company today has entered into a Supply Agreement with Celgene …

Read more